An observational study in Glioblastoma, sponsored by Centre Hospitalier Universitaire de la Réunion. Recruiting at 1 site in Reunion. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Centre Hospitalier Universitaire de la Réunion · Observational
To date, very little data exists on gliomas in the Réunion population, in terms of epidemiology, socio-cultural aspects, clinical or biological factors, and care pathways. However, the Réunion population is multicultural and highly cosmopolitan, experiencing rapid aging, and its socio-economic indicators are among the most pessimistic of all French departments. Furthermore, the healthcare services available on the island are less comprehensive than those in metropolitan France (Insee 2018). Finally, the management of patients with gliomas, particularly high-grade gliomas, remains very complex, with significant medical and social challenges (supportive care, end-of-life care, etc.). Healthcare professionals agree that these specialized facilities are insufficient to meet the care needs in Réunion (post-acute care, palliative care units, supportive care, etc.).
GlioRun is a retrospective and prospective mixed-methods cohort study, combining epidemiological and socio-anthropological approaches, which aims to produce data to improve care and the experiences of patients and their relatives on Reunion Island, and reduce the number of medical evacuations to mainland France.
1,920 studies on the registry are indexed under Glioblastoma; 450 are open to participants now.
This study's planned enrollment of 214 is above the median of 60 across 188 observational studies indexed under Glioblastoma.
Browse Glioblastoma studies →Centre Hospitalier Universitaire de la Réunion is the lead sponsor of 138 studies on the registry; 36 are open to participants now.
Counted across the registry records on this site, refreshed daily.
person with glioma at La Réunion Island
Quantitative study (retrospective and prospective components):
Patients aged 18 and over:
Socio-anthropological study (prospective component):
Patients:
Healthcare Professional:
Exclusion Criteria:
Regarding the quantitative study:
Patient:
Refusing to participate in the quantitative study Having a recurrent diffuse glioma Person deprived of their liberty and judgment by judicial or administrative decision, and person subject to a legal protection measure: guardianship or curatorship, under judicial protection, under legal guardianship, etc.)
Regarding the socio-anthropological study:
Patient:
Refusing to participate in the qualitative study Does not speak French Having serious somatic or mental health problems incompatible with the interview Healthcare professionals: Refusing to participate in the study
Distribution of sociodemographic characteristics at diagnosis
Distribution of age at diagnosis (years), sex (male/female), ethnicity, and socioeconomic indicators among patients diagnosed with diffuse glioma in Réunion Island
Time frame: two years
Clinical presentation of diffuse gliomas at diagnosis
Clinical characteristics at diagnosis including presenting symptoms, performance status (e.g., Karnofsky Performance Status score), tumor location, and initial treatment modalities
Time frame: 2 years
Molecular characteristics of diffuse gliomas
Tumor molecular markers including IDH mutation status, 1p/19q codeletion status, and MGMT promoter methylation status assessed at diagnosis
Time frame: inclusion
Histopathological classification of diffuse gliomas
Histopathological classification of tumors according to the WHO classification of central nervous system tumors at diagnosis
Time frame: inclusion
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de la Réunion